1366002-50-7
1366002-50-7
Chemical Structure
Senexin A
- CAS No.: 1366002-50-7
- Formula:C17H14N4
- Molecular Weight:274.32
IUPAC Name: 4-(phenethylamino)quinazoline-6-carbonitrile
InChIKey: XBJCNHGQFJFCOY-UHFFFAOYSA-N
SMILES: N#CC1=CC=C2C(C(NCCC3=CC=CC=C3)=NC=N2)=C1
Biological Activity: Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Senexin A | 99.58% | Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804. [Content Brief]
- [2]. Ho TY, et al. The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo. Biomed Pharmacother. 2023 Jun;162:114667. [Content Brief]
